A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata (AA)

A Phase I/II Study Of The Efficacy,Safety and Pharmacokinetics Of Jaktinib Hydrochloride Cream In Subjects With Mild To Moderate Alopecia Areata

This study includes a dose escalation part(phase I) and a dose extension part(phase II).

Study Overview

• Status: Active, not recruiting
• Conditions: Alopecia Areata(AA)
• Intervention / Treatment: Drug: Placebo; Drug: Jaktinib hydrochloride cream

Detailed Description

In phase I of this study, a multi-center, randomized, placebo parallel control design was adopted. Enrolled subjects were randomly assigned to the experimental group or the placebo group.A total of 40 subjects are expected to be enrolled in about 4 centers.

In phase II of this study, a multi-center, randomized, double-blind parallel, placebo-controlled design was adopted. Enrolled subjects were randomly assigned to the experimental group or the placebo group.About 120 subjects are expected to be enrolled in about 10 centers.

• Study Type: Interventional
• Enrollment (Actual): 160
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• China
  • Hunan
    • Changsha, Hunan, China, 410011
      • The Second Xaingya Hospital，central south university

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• 18 ~ 65 years old (including boundary value), regardless of gender;
• Diagnosis of Alopecia Areata;
• Hair loss accounts for 5% ~ 49% of the total scalp area;
• The duration of hair loss is at least 6 months, the longest is not more than 5 years;
• Patients can complete treatment for at least 6 months;
• About Fertility needs meet the following criteria: The results of serum pregnancy tests performed by fertile women during screening visits must be negative, and the results of human chorionic gonadotropin tests performed before the initiation of the study drug must be negative;Women who were fertile and men who had not received vasectomies were required to use effective contraception throughout the study period beginning with the informed consent and up to six months after the last administration;
• Subjects will voluntarily participate in the study after learning about the content and potential adverse drug reactions and must sign an IRC-approved informed consent prior to beginning any examination required by the study;
• Subject is willing and able to comply with scheduled visits, treatment plan, study drug administration, and other study procedures.

Exclusion Criteria:

• The following causes of hair loss should be excluded: hair loss caused by androgenic alopecia,syphilis, thyroid diseases, etc.
• Acute Diffuse and Total Alopecia of the Female Scalp;
• Prior history of serious chronic diseases, such as thyroid disease, liver disease, malnutrition, heart disease, nervous system disease, gastrointestinal dysfunction, tumor and mental illness, etc;
• Human immunodeficiency virus infection, hepatitis C virus infection, hepatitis B virus infection;
• Participated in a trial for a topical or oral JAK inhibitor;
• Allergic reactions to active ingredients or excipients are known or determined by the investigator;
• Receipt of treatment known to potentially affect the course of AA within last 3 month;
• In the opinion of the investigator , the subject is inappropriate for entry into this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Dose extension: Placebo; Placebo, twice daily	Drug: Placebo; Dose extension: Placebo
Experimental: Cohort 1,0.5% Bid; Jaktinib hydrochloride cream 0.5% concentration, twice daily	Drug: Jaktinib hydrochloride cream; Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks; Other Names: Jaktinib
Experimental: Cohort 1,1.5% Bid; Jaktinib hydrochloride cream 1.5% concentration, twice daily	Drug: Jaktinib hydrochloride cream; Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks; Other Names: Jaktinib
Experimental: Cohort 1,2.5% Qd; Jaktinib hydrochloride cream 2.5% concentration, once daily	Drug: Jaktinib hydrochloride cream; Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks; Other Names: Jaktinib
Experimental: Cohort 1,2.5% Bid; Jaktinib hydrochloride cream 2.5% concentration, twice daily	Drug: Jaktinib hydrochloride cream; Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks; Other Names: Jaktinib
Experimental: Dose extension: 1.5% Bid; Jaktinib hydrochloride cream 1.5% concentration, twice daily	Drug: Jaktinib hydrochloride cream; Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks; Other Names: Jaktinib
Experimental: Dose extension: 2.5% Bid; Jaktinib hydrochloride cream 2.5% concentration, twice daily	Drug: Jaktinib hydrochloride cream; Jaktinib hydrochloride cream/placebo applied topically in the morning and in the evening, administered continuously for 24 weeks; Other Names: Jaktinib

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants Achieving 90% Improvement of Severity of Alopecia Tool (SALT90)	SALT is a quantitative assessment of alopecia areata (AA) severity based on the scalp hair loss. A SALT 90 response is a 90% or greater reduction from baseline in SALT score. The SALT score can vary from 0 to 100%, with higher scores representing increasing severity of disease.	at week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Severity of Alopecia Tool (SALT) Score	Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system. The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area. The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area. The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome. The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss).	at baseline, at week 12 and at week 24

Collaborators and Investigators

• Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
• Investigators: Study Chair: qianjin lu, M.D., The Second Xiangya Hospital, Central South University

Study record dates

Study Major Dates

• Study Start (Actual): August 12, 2020
• Primary Completion (Estimated): December 1, 2024
• Study Completion (Estimated): December 1, 2024

Study Registration Dates

• First Submitted: June 19, 2020
• First Submitted That Met QC Criteria: June 22, 2020
• First Posted (Actual): June 24, 2020

Study Record Updates

• Last Update Posted (Actual): March 6, 2024
• Last Update Submitted That Met QC Criteria: March 4, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Pathological Conditions, Anatomical; Hypotrichosis; Hair Diseases; Alopecia; Alopecia Areata
• Other Study ID Numbers: ZGJAKT001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No